Palliative Radiotherapy in Metastatic Breast Cancer Patients on CDK4/6 Inhibitors: Safety Analysis
Authors:
- Furkan CeylanFCFurkan Ceylan
- Mirmehdi MehdiyevMMMirmehdi Mehdiyev
- Burak BilginBBBurak Bilgin
- Ateş Kutay TenekeciATAteş Kutay Tenekeci
- Bülent YalçınBYBülent Yalçın
- M. Bülent AkıncıMAM. Bülent Akıncı
- Didem Şener DedeDDDidem Şener Dede
- Mehmet Ali Nahit ŞendurMŞMehmet Ali Nahit Şendur
- Efnan AlgınEAEfnan Algın
- Şebnem YücelŞYŞebnem Yücel
Open Access
Abstract
Purpose: CDK4/6 inhibitors require meticulous monitoring due to their potential to cause hematological toxicities and hepatotoxicity. This study evaluates the safety of combining CDK4/6 inhibitors with palliative radiotherapy in patients with metastatic hormone receptor-positive and HER2-negative breast cancer. Patients and Methods: This study included 188 patients treated with CDK4/6 inhibitors between January 2021 and June 2024. Data on patient demographics, tumor characteristics, and treatment interventions were extracted from medical records. The primary focus was on the incidence of grade ≥ 3 hematologic toxicities and hepatotoxicity, assessed according to CTCAE 5.0 criteria, in those receiving concurrent palliative radiotherapy. Results: With a median follow-up of 18.5 months, the 18-month PFS and OS rates were 67% and 85%, respectively. The median age was 57.5 years, and 79% of patients were post-menopausal. Bone and liver metastases were present in 66% and 23% of patients, respectively. Concurrent palliative radiotherapy was administered in 25% of the cohort. The incidence of grade ≥ 3 hematologic toxicity was comparable between those who received radiotherapy and those who did not. Ribociclib use was associated with lower rates of grade 3 hematologic toxicity (OR: 0.37), neutropenia (OR: 0.41), dose interruptions (OR: 0.30), and dose reductions (OR: 0.37). Pre-menopausal status was linked to fewer dose reductions (OR: 0.17). Rates of treatment interruption, dose reduction, and withdrawal were 55%, 24%, and 2%, respectively. Conclusions: The concurrent use of CDK4/6 inhibitors and palliative radiotherapy does not increase the incidence of hematological adverse events in patients with metastatic breast cancer.Keywords
This publication has 29 references indexed in Scilit:
- Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysisRadiotherapy and Oncology, 2023
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialThe Lancet Oncology, 2022
- Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4European Journal of Cancer, 2022
- Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2022
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020
- CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastasesJournal of Neuro-Oncology, 2019
- Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel CombinationAdvances in Radiation Oncology, 2019
- Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based GuidelinePractical Radiation Oncology, 2017
- DNA damage induced by the direct effect of radiationRadiation Physics and Chemistry, 2008
- Checkpoint signalling: focusing on 53BP1Nature Cell Biology, 2002